Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis
Chengzhi Zhou,Yilin Yang,Xinqing Lin,Nianxin Fang,Likun Chen,Juhong Jiang,Haiyi Deng,Yu Deng,Minghui Wan,Guihuan Qiu,Ni Sun,Di Wu,Xiang Long,Changhao Zhong,Xiaohong Xie,Zhanhong Xie,Ming Liu,Ming Ouyang,Yinyin Qin,Francesco Petrella,Alfonso Fiorelli,Sara Bravaccini,Satoshi Watanabe,Taichiro Goto,Piergiorgio Solli,Hitoshi Igai,Yuichi Saito,Nikolaos Tsoukalas,Takeo Nakada,Shiyue Li,Rongchang Chen,Yuki KATAOKA
DOI: https://doi.org/10.3389/fimmu.2022.935779
IF: 7.3
2022-07-21
Frontiers in Immunology
Abstract:BACKGROUND: Checkpoint inhibitor–related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined. METHODS: We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase's characteristics. RESULTS: There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: ≤4.9 weeks; subacute phase: 4.9~13.1 weeks; and chronic phase: ≥13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the CIP grade and Performance Status score decreased (P<0.05). The main change in radiologic features was the absorption of the lesions, and 3 (3/11) patients in the chronic phase had persistent traction bronchiectasis. For histologic features, most patients had acute fibrinous pneumonitis in the acute phase (5/8), and most had organizing pneumonia in the subacute phase (5/6). Other histologic changes advanced over time, with the lesions entering a state of fibrosis. Moreover, the levels of interleukin-6, interleukin-10 and high-sensitivity C-reactive protein (hsCRP) increased in the acute phase and decreased as CIP progressed (IL-6: 17.9 vs. 9.8 vs. 5.7, P=0.018; IL-10: 4.6 vs 3.0 vs. 2.0, P=0.041; hsCRP: 88.2 vs. 19.4 vs. 14.4, P=0.005). CONCLUSIONS: The general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.
immunology